Investigators reported detection of high-risk human papillomavirus (HPV) DNA in 60 of 191 participants, a prevalence of 31.4% (95% CI 25.3%–38.3%). The study team observed that half of those who tested positive (30/60) carried multiple serotypes. The most common genotype identified was HPV 52, followed by HPV 16 and HPV 51. Authors noted that only 30% of HPV-positive women harbored genotypes 16 or 18, the two types targeted by the bivalent vaccine; the remaining majority comprised non-16/18 high-risk genotypes. These genotype data emerged from endocervical swab testing and were presented without further stratification by age or immunologic status in the abstract.
The cohort comprised 191 women living with HIV aged 25–65 years who attended the HIV clinic at Connaught Teaching Hospital in Freetown between September and December 2024. The mean age was 36.8 years. Demographic details reported in the abstract include 44.5% of participants being single and 67% being employed. Endocervical swabs were collected from enrolled women for HPV DNA testing. Data management and statistical analyses used R (v4.4.0), according to the methods reported. The article states ethical approval was obtained from the Sierra Leone Ethics and Scientific Review Committee (SLESRC NO: 012/07/2023) and that all participants provided written informed consent.
Logistic regression analysis identified former contraceptive use as independently associated with increased odds of HPV positivity. The study team reported an adjusted odds ratio (aOR) of 4.86 with a 95% confidence interval of 1.65–17.37 and p = 0.0032. The abstract does not provide detail on other candidate variables included in the multivariable model, nor does it list crude odds ratios or the full set of covariates considered. The authors therefore focused on former contraceptive use as the single independent predictor highlighted in the results summary.
Data indicated a substantial burden of high-risk HPV among HIV-positive women at a single tertiary clinic in Freetown. The predominance of non-16/18 genotypes, particularly HPV 52, suggests that vaccines that only target types 16 and 18 would not cover the majority of infections detected in this cohort. The study team argued for integration of HPV screening into HIV care services in Sierra Leone and raised the need to consider broader HPV vaccine coverage for the local genotype distribution. The authors did not provide programmatic details on how such integration might be operationalized or costed; those implementation specifics were not reported in the abstract.
This report is a single-site, cross-sectional analysis presented as a preprint; it has not undergone peer review. The abstract does not report stratified prevalence by age group, CD4 count, HIV viral load, duration of antiretroviral therapy, or details of contraceptive types and timing—information that would clarify potential biological or behavioral confounders. The methods section summarized in the abstract lists endocervical sampling and HPV DNA testing but does not describe the testing platform, genotype panel, or laboratory quality controls. The multivariable model result for former contraceptive use is provided without the complete list of adjusted covariates or model diagnostics in the abstract.
Open questions remain and are directly relevant to clinical practice and policy in Sierra Leone: which specific contraceptive methods were associated with increased HPV detection, and is that association causal or confounded by sexual behavior or healthcare access? How does HPV prevalence vary by immune status, ART use, or duration of HIV infection? Would broader-valent HPV vaccines substantially alter projected prevention outcomes for this population, given the genotype mix observed? The authors stated that data will be made available upon request to the corresponding author; however, peer review and fuller reporting will be necessary to evaluate generalizability and to inform programmatic decisions.
Ethical approval and consent processes were reported (SLESRC NO: 012/07/2023). The preprint was posted November 13, 2026, and the authors declared no competing interests. These findings highlight measurable gaps in screening integration and vaccine match for women living with HIV in Sierra Leone, but the observational, single-center nature of the study and incomplete methodological details in the abstract limit immediate clinical application until the full manuscript and peer review are available.